BRIAN HOWARD: Open Payments
NPI 1679934871 · SEARCY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,193 in 63 payments from 9 companies in 2025. Trend: 2023 $990 · 2024 $790 · 2025 $1,193
Food & beverage: $1,193
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $498 |
| E.R. Squibb & Sons, L.L.C. | 10 | $169 |
| Vanda Pharmaceuticals Inc. | 7 | $145 |
| Neurocrine BioSciences, Inc. | 6 | $127 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $115 |
| Lundbeck LLC | 3 | $60 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Alkermes, Inc. | 1 | $14 |
Products named: VRAYLAR, COBENFY, INGREZZA, FANAPT, CAPLYTA, REXULTI, UZEDY, HETLIOZ.
Industry payments across AR — which companies pay providers there.
